Interview with Dr. Elliott Richelson

Researchers at Mayo Clinic's campus in Jacksonville and Virginia Tech in Blacksburg, Va., through their technology commercialization efforts, have licensed compounds to AstraZeneca for potential new drug therapies to treat depression. The collaboration advances both the development of novel compounds and supports ongoing research by Mayo and Virginia Tech in the area of triple reuptake inhibitors.

Read More: Mayo Invention Collaboration Focuses on New Treatment For Depression


Annual Meeting

Program CoverThe ACNP Annual Meeting is one of the world's leading forums for the exchange of cutting edge scientific information about the brain, behavior, and psychotropic drugs.

ACNP Publications

Program CoverThe College offers a variety of Publications with the latest and most comprehensive research in psychopharmacology and related fields.

Research Discussions

This forum enables discussion of articles that have appeared in Neuropsychopharmacology. It is intended to stimulate scholarly interactions among researchers, and to help educate members of the public who are interested in psychiatric illness.